12-88049228-ACT-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM4BS2
The NM_025114.4(CEP290):โc.7394_7395delโ(p.Glu2465ValfsTer2) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000307 in 1,604,266 control chromosomes in the GnomAD database, including 5 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: ๐ 0.00015 ( 0 hom., cov: 32)
Exomes ๐: 0.00032 ( 5 hom. )
Consequence
CEP290
NM_025114.4 frameshift
NM_025114.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.74
Genes affected
CEP290 (HGNC:29021): (centrosomal protein 290) This gene encodes a protein with 13 putative coiled-coil domains, a region with homology to SMC chromosome segregation ATPases, six KID motifs, three tropomyosin homology domains and an ATP/GTP binding site motif A. The protein is localized to the centrosome and cilia and has sites for N-glycosylation, tyrosine sulfation, phosphorylation, N-myristoylation, and amidation. Mutations in this gene have been associated with Joubert syndrome and nephronophthisis and the presence of antibodies against this protein is associated with several forms of cancer. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM4
Frameshift in the end of transcript resulting in stoplost. Downstream stopcodon found after 2478 codons.
BS2
High Homozygotes in GnomAdExome4 at 5 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CEP290 | NM_025114.4 | c.7394_7395del | p.Glu2465ValfsTer2 | frameshift_variant | 54/54 | ENST00000552810.6 | |
RLIG1 | NM_001009894.3 | c.*809_*810del | 3_prime_UTR_variant | 7/7 | ENST00000356891.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CEP290 | ENST00000552810.6 | c.7394_7395del | p.Glu2465ValfsTer2 | frameshift_variant | 54/54 | 1 | NM_025114.4 | P4 | |
RLIG1 | ENST00000356891.4 | c.*809_*810del | 3_prime_UTR_variant | 7/7 | 1 | NM_001009894.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 151880Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
22
AN:
151880
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000598 AC: 144AN: 241004Hom.: 2 AF XY: 0.000826 AC XY: 108AN XY: 130746
GnomAD3 exomes
AF:
AC:
144
AN:
241004
Hom.:
AF XY:
AC XY:
108
AN XY:
130746
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000323 AC: 469AN: 1452268Hom.: 5 AF XY: 0.000452 AC XY: 326AN XY: 721668
GnomAD4 exome
AF:
AC:
469
AN:
1452268
Hom.:
AF XY:
AC XY:
326
AN XY:
721668
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000151 AC: 23AN: 151998Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74312
GnomAD4 genome
AF:
AC:
23
AN:
151998
Hom.:
Cov.:
32
AF XY:
AC XY:
18
AN XY:
74312
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3462
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:4Benign:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1Benign:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2016 | - - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The CEP290 p.Glu2465Valfs*2 variant was not identified in the literature but was identified in dbSNP (ID: rs569673313) and ClinVar (classified as benign by Invitae; as likely pathogenic by CeGaT Praxis; and as uncertain significance by GeneDx and Shahid Beheshti University of Medical Sciences). The variant was identified in control databases in 144 of 241004 chromosomes (2 homozygous) at a frequency of 0.0005975 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: South Asian in 119 of 28430 chromosomes (freq: 0.004186), European (non-Finnish) in 21 of 108954 chromosomes (freq: 0.000193), Ashkenazi Jewish in 1 of 9878 chromosomes (freq: 0.000101) and Latino in 3 of 33318 chromosomes (freq: 0.00009), but was not observed in the African, East Asian, European (Finnish), or Other populations. The c.7394_7395del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 2465 and leads to a premature stop codon at position 2. This variant occurs in the last exon of the CEP290 gene, therefore it is not expected to result in loss of function. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 27, 2016 | A variant of uncertain significance has been identified in the CEP290 gene. The c.7394_7395delAG variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The c.7394_7395delAG variant is observed in 72/16,502 (0.4%) alleles from individuals of South Asian background (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The c.7394_7395delAG variant causes a frameshift starting with codon Glutamic acid 2465, changes this amino acid to a Valine residue and creates a premature Stop codon at position 2 of the new reading frame, denoted p.Glu2465ValfsX2. This variant is predicted to cause loss of normal protein function through protein truncation as the last 15 amino acids of the CEP290 protein and lost and replaced with 1 incorrect amino acid. However, this deletion occurs in a region that is not conserved. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 02, 2024 | Variant summary: CEP290 c.7394_7395delAG (p.Glu2465ValfsX2) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 0.00031 in 1604266 control chromosomes, predominantly at a frequency of 0.0042 within the South Asian subpopulation in the gnomAD database, including 5 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 3.76 fold of the estimated maximal expected allele frequency for a pathogenic variant in CEP290 causing Meckel Syndrome Type 4 phenotype (0.0011). c.7394_7395delAG has been reported in the literature in individuals with molecular diagnosis of Joubert syndrome or clinical diagnosis of nonsyndromic retinal dystrophy (Iyer_2022, Testa_2021). Additional patients with retinitis pigmentosa or clinical features of Joubert Syndrome have been reported in the heterozygous state (Bohorquez_2021, Devi_2020), an insufficient genotype. These reports do not provide unequivocal conclusions about association of the variant with Meckel Syndrome Type 4. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 34327195, 32139166, 35123515, 22848652, 34196655). ClinVar contains an entry for this variant (Variation ID: 372319). Based on the evidence outlined above, the variant was classified as benign. - |
CEP290-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 10, 2024 | The CEP290 c.7394_7395delAG variant is predicted to result in a frameshift and premature protein termination (p.Glu2465Valfs*2). This deletion is near the C-terminus of the CEP290 protein and is predicted to result in a protein that is 12 amino acids shorter than the reference protein. This variant has been reported as a variant of uncertain significance in a large cohort study of patients with obesity (Savas et al. 2019. PubMed ID: 31216558). This variant is reported in 0.42% of alleles in individuals of South Asian descent in gnomAD, including two homozygotes. This population data provides evidence against pathogenicity. However, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Bardet-Biedl syndrome 14 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Aug 07, 2018 | - - |
Joubert syndrome 5 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Aug 07, 2018 | - - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis;C0687120:Nephronophthisis Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at